The history and future of pharmacogenetics in Aotearoa/New Zealand

被引:0
作者
Kennedy, Martin A. [1 ,2 ]
机构
[1] Univ Otago, Carney Ctr Pharmacogen, Christchurch, New Zealand
[2] Univ Otago, Dept Pathol & Biomed Sci, Gene Struct & Funct Lab, Christchurch, New Zealand
关键词
Adverse drug reaction; direct-to-consumer; drug prescribing; genetic test; personalised medicine; pharmacogenomics; MALIGNANT HYPERTHERMIA; PERSONALIZED MEDICINE; CYP2C19; VARIANTS; POLYMORPHISM; GENOTYPE; CYP2D6; METHYLTRANSFERASE; GENE; IMPLEMENTATION; DEBRISOQUINE;
D O I
10.1080/03036758.2024.2406824
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pharmacogenetics is the study of genetic variants in genes which may impact on the outcome of drug treatment, either through safety considerations (occurrence of adverse drug reactions or therapeutic failure) or altered drug pharmacokinetics. This paper provides a brief history of pharmacogenetics research in the Aotearoa/New Zealand context, and a commentary on our current state. Factors that have limited translation of pharmacogenetic knowledge into ou r healthcare system are considered, and possible solutions to these are proposed. Pharmacogenetic knowledge has long been invoked as a way to improve the safety and success of drug prescribing, but (with some notable exceptions) it has largely failed to achieve this promise. Several barriers to clinical implementation need to be overcome to ensure that pharmacogenetics becomes a key component of precision health for all people in Aotearoa/New Zealand.
引用
收藏
页数:18
相关论文
共 99 条
[1]   The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups [J].
Alrajeh, Khalifa Y. ;
Roman, Youssef M. .
PERSONALIZED MEDICINE, 2022, :327-339
[2]   PharmGKB summary: very important pharmacogene information for RYR1 [J].
Alvarellos, Maria L. ;
Krauss, Ronald M. ;
Wilke, Russell A. ;
Altman, Russ B. ;
Klein, Teri E. .
PHARMACOGENETICS AND GENOMICS, 2016, 26 (03) :138-144
[3]  
Australasia RCoPo, 2024, Pharmacogenomic Indications in Australia
[4]   Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature [J].
Berm, Elizabeth J. J. ;
de Looff, Margot ;
Wilffert, Bob ;
Boersma, Cornelis ;
Annemans, Lieven ;
Vegter, Stefan ;
van Boven, Job F. M. ;
Postma, Maarten J. .
PLOS ONE, 2016, 11 (01)
[5]   PharmVar GeneFocus: CYP2C19 [J].
Botton, Mariana R. ;
Whirl-Carrillo, Michelle ;
Del Tredici, Andria L. ;
Sangkuhl, Katrin ;
Cavallari, Larisa H. ;
Agundez, Jose A. G. ;
Duconge, Jorge ;
Lee, Ming Ta Michael ;
Woodahl, Erica L. ;
Claudio-Campos, Karla ;
Daly, Ann K. ;
Klein, Teri E. ;
Pratt, Victoria M. ;
Scott, Stuart A. ;
Gaedigk, Andrea .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) :352-366
[6]   Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection [J].
Bousman, Chad A. ;
Zierhut, Heather ;
Muller, Daniel J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (02) :309-312
[7]   Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools [J].
Bousman, Chad A. ;
Dunlop, Boadie W. .
PHARMACOGENOMICS JOURNAL, 2018, 18 (05) :613-622
[8]   A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree [J].
Brown, RL ;
Pollock, AN ;
Couchman, KG ;
Hodges, M ;
Hutchinson, DO ;
Waaka, R ;
Lynch, P ;
McCarthy, TV ;
Stowell, KM .
HUMAN MOLECULAR GENETICS, 2000, 9 (10) :1515-1524
[9]   Current state and future prospects of direct-to-consumer pharmacogenetics [J].
Chua, E. W. ;
Kennedy, M. A. .
FRONTIERS IN PHARMACOLOGY, 2012, 3
[10]   Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes [J].
Chua, Eng Wee ;
Harger, Simon P. ;
Kennedy, Martin A. .
FRONTIERS IN PHARMACOLOGY, 2019, 10